がん/腫瘍プロファイリング市場：技術、バイオマーカータイプ、がんタイプ、アプリケーション別-2024-2030年の世界予測

がん/腫瘍プロファイリング市場規模は2023年に107億9,000万米ドルと推計され、2024年には127億7,000万米ドルに達し、CAGR 18.74％で2030年には359億4,000万米ドルに達すると予測されています。

がん/腫瘍プロファイリングは、腫瘍内の特定のタンパク質、遺伝子、その他の分子を分析し、遺伝子変異などの遺伝的または分子的変化に関する情報を提供する検査法です。腫瘍プロファイリングは、患者の腫瘍の経路が利用可能な標的治療と一致するかどうかを判断するために腫瘍医が広く使用している技術です。がん患者の治療におけるバイオマーカーの利用が加速し、カスタマイズされたがん治療への嗜好が高まっていることと、政府や国際機関ががん診断法の開発に力を入れていることが、がん/腫瘍プロファイリング技術の普及を後押ししています。一方、がん/腫瘍プロファイリングツールやサービスに対する設備投資が高く、バイオマーカーの発見から承認までの割合が低いことが市場開拓の妨げとなっています。しかし、次世代シーケンシングの普及、腫瘍プロファイリングの改善、ポイントオブケアがん検出技術の拡大により、今後数年で利用が急増すると予想されます。

テクノロジーさまざまながんの遺伝子変化を調べるための次世代シーケンサー（NGS）の採用

免疫測定法は、サンプル中の分析対象物の存在と濃度を測定するのに役立つため、腫瘍プロファイリングを大規模に実施するアプリケーションの増加により、がん腫瘍プロファイリング市場の技術分野で優位を占めています。蛍光in-situハイブリダイゼーション（FISH）および発色in-situハイブリダイゼーション（CISH）を含むin-situハイブリダイゼーション（ISH）は、標識した相補的DNAまたはRNA鎖を使用して、染色体上またはスライドに固定した組織の一部（in-situ）に特定のDNAまたはRNA配列を局在させる。FISHプロファイリングは、従来のアプローチよりも時間がかからず、染色体の微小欠失、増幅、転座を簡単に調べることができます。質量分析に基づく調査は、プロテオームやメタボロームの微妙な変化を検出するために、がん研究においてますます使用されるようになってきています。対照的に、マイクロアレイはがん細胞の遺伝的およびエピジェネティックな構成を理解するために広く使用されており、腫瘍細胞における小さな遺伝的変化を同定するために利用されています。次世代シーケンサー（NGS）の開発は、様々ながんにおける遺伝子変化を効果的に探索し、いくつかの遺伝的またはエピジェネティックな変異を同定して、疾患の早期診断のための新しいバイオマーカーを開発するのに役立っています。ポリメラーゼ連鎖反応（PCR）は、遺伝子や染色体における特定の変化を調べるために使用され、遺伝的状態やがんなどの疾患の発見と診断に役立ちます。さらに、転移病変の早期発見を可能にする画像診断や生化学的プロセスの技術的進歩は、がん治療においてより高い成功率をもたらす可能性があります。

バイオマーカーの種類：遺伝子の発現、遺伝子機能、遺伝子制御の測定にゲノムバイオマーカーを用います。

ゲノムバイオマーカーは、遺伝子の発現、遺伝子機能、遺伝子制御の測定と呼ぶことができ、検査によって、ある人のがんがEGFR阻害剤で治療可能な推定糸球体濾過量（EGFR）遺伝子変異を有するかどうかを決定することができ、また臨床試験における新しいがん治療法の研究に役立ちます。理想的ながんバイオマーカーは、健康な患者を除き、患者の血液や尿から検出しやすいタンパク質やタンパク質断片であり得る。さらに、がんバイオマーカーは数多く存在し、それらは別々に体内で働き、治療に対する反応も異なります。これらのがんバイオマーカーには、遺伝子変異（変化）、遺伝子再配列、遺伝子の余分なコピー、遺伝子の欠損、その他いくつかの分子が含まれることもあります。

がんの種類：予測モデリングおよび臨床的リスク層別化のための前立腺がんにおけるがんプロファイリングの幅広い選好

がん/腫瘍プロファイリングは、乳がんにおいて複数のレベルで疾患管理に不可欠な要素となっています。遺伝子検査は、悪性腫瘍の家族歴を有する患者における遺伝性がん症候群を同定し、乳がん予防の成功に寄与します。大腸がん（CRC）の分子プロファイリングには、がんの病態や標的治療に関する重要な情報を提供するという利点があります。転移性CRC（mCRC）治療の状況は、化学療法が依然として治療の基幹であるにもかかわらず、その不均一性と分子設計図の理解とともに変わりつつあります。推定糸球体濾過量（EGFR）、RET、MET、BRAF、未分化リンパ腫キナーゼ（ALK）など、肺がんに共通する遺伝子変異を検出することができ、患者への標的治療の提供につながります。皮膚黒色腫（CM）の遺伝子発現プロファイリング（GEP）に基づく分子予測検査は感受性が高く、生物学的挙動を予測できる可能性があります。さらに、前立腺がんのがん/腫瘍プロファイリングは、予測モデリングと臨床的リスク層別化のための信頼できる方法として、最近になって登場しました。前立腺腫瘍の統合的ゲノム・プロファイリングは、プレシジョン・メディシンの新時代における疾患理解を向上させる包括的な情報と新たな発見を提供しています。

アプリケーション治癒と回復時間を改善する精密医療の開発におけるがん/腫瘍プロファイリングの使用増加

がん/腫瘍プロファイリングは、治療標的や分子バイオマーカーを特定することで、臨床腫瘍学を大きく発展させ、多くの一般的な腫瘍や希少な腫瘍の転帰を著しく改善し、がん治療の個別化を導きました。がん/腫瘍プロファイリングは通常、患者の遺伝的体質に合った精密医療を開発し、治癒と回復時間を改善するために使用されます。新しく複雑な技術の応用とバイオマーカーの臨床応用により、バイオマーカーの発見と開発がアップグレードされ、診断、予後、疾患のモニタリングが改善されます。研究者たちは、がん治療を合理化するために、より精密で的を絞った技術を求めており、そのため迅速診断プロバイダーは、高度に洗練されたがんプロファイリングアプローチを求めるようになっています。ゲノムに基づく予後バイオマーカーは、臨床段階におけるいくつかのがん種の予後予測に使用され、薬剤や治療法の開発にも役立っています。がん/腫瘍プロファイリングはがんのスクリーニングにも役立ち、がんの早期発見、早期管理、そして治癒の可能性にも役立ちます。さらに、がん/腫瘍プロファイリングは、バイオマーカーの高感度かつ正確な検出を提供し、非侵襲的な疾患診断や治療反応モニタリングのための信頼性の高いアプローチを持っています。

地域別インサイト

北米、EU、GCC、アジア太平洋地域の先進諸国におけるがん/腫瘍プロファイリング市場情勢は、著名な市場参入企業や確立された規制フレームワーク、患者ケアを向上させながらがんの負担を軽減するために政府が開始したイニシアチブにより、非常に進んでいます。がん診断への投資が増え続ける中、がんプロファイリングは世界の新興経済諸国で徐々に脚光を浴びつつあります。米国がん協会によると、米国では2023年に約190万人のがん患者が新たに診断されると予測されており、がんプロファイリングの必要性が高まっています。北欧や西欧諸国では、ヘルスケアへの投資が高いことを反映して、バイオマーカー検査の利用率や利用可能性がかなり高いです。各国の市場関係者は、米国や欧州諸国の技術プロバイダーと協力し合い、がんの診断、プロファイリング、治療法の進歩に貢献しています。さらに、現在進行中のキャンペーンやがん啓発プログラムは、アジア諸国におけるがん/腫瘍プロファイリングの必要性を浮き彫りにしています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはがん/腫瘍プロファイリング市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、がん/腫瘍プロファイリング市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.がん/腫瘍プロファイリング市場の市場規模および予測は？

2.がん/腫瘍プロファイリング市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.がん/腫瘍プロファイリング市場の技術動向と規制枠組みは？

4.がん/腫瘍プロファイリング市場における主要ベンダーの市場シェアは？

5.がん/腫瘍プロファイリング市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん患者の治療におけるバイオマーカーの採用増加
    • がん診断法の開発に向けた政府および国際機関の取り組みの有無
    • がん治療における個別化医療への関心の高まり
  • 抑制要因
    • がん/腫瘍プロファイリング機器およびサービスへの多額の資本投資
  • 機会
    • 次世代シーケンシングの出現と腫瘍プロファイリングの進歩
    • がん検出を向上させるためのポイントオブケア診断技術の改善
  • 課題
    • バイオマーカーの発見から承認までの比率が低い
• 市場セグメンテーション分析
  • 技術：次世代シーケンシング（NGS）を活用した様々ながんの遺伝子変異の探索
  • バイオマーカーの種類：遺伝子の発現、遺伝子機能、遺伝子調節の測定にゲノムバイオマーカーを使用する
  • がんの種類：予測モデルと臨床リスク層別化のための前立腺がんのがんプロファイリングが広く推奨されています
  • 応用：治癒と回復時間を改善するための精密医療の開発におけるがん/腫瘍プロファイリングの使用の増加
• 市場動向分析
  • がん診断に対する政府の取り組みとがん/腫瘍プロファイリングソリューションの急速な進歩
  • がん罹患率の上昇とがん調査の進展により、アジア太平洋地域では新たながん/腫瘍プロファイリングの必要性が高まっています。
  • EMEA地域全体でがんの負担を克服するために、精密医薬品と遺伝子プロファイリングソリューションの採用が増加
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 がん/腫瘍プロファイリング市場：技術別

• 免疫学的検査
• インサイチューハイブリダイゼーション
• 質量分析
• マイクロアレイ
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 がん/腫瘍プロファイリング市場バイオマーカーの種類別

• ゲノムバイオマーカー
• タンパク質バイオマーカー

第8章 がん/腫瘍プロファイリング市場がんの種類別

• 乳がん
• 大腸がん
• 肺がん
• メラノーマがん
• 前立腺がん

第9章 がん/腫瘍プロファイリング市場：用途別

• バイオマーカーの発見
• 臨床応用
• 診断
• 個別化医療
• 予測
• 調査
• ふるい分け
• 治療とモニタリング

第10章 南北アメリカのがん/腫瘍プロファイリング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん/腫瘍プロファイリング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん/腫瘍プロファイリング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • アジレントとNCCS、アジアで多くみられるがんに関するシンガポールのゲノムプロファイリングを推進するための調査協力契約を締結
  • ソフィア・ジェネティクス、アジレントとがん分析製品で提携
  • Point32HealthとFoundation Medicineが進行がん患者への包括的ゲノムプロファイリングへのアクセスを拡大
  • シナジーラボラトリーズ、新たながんプロファイリングソリューションにSOPHiA GENETICSの技術を採用
  • Exact Sciences、米国でOncoExTraがん治療選択検査を開始
  • カリスライフサイエンス、4億米ドルの調達で総資金調達額20億米ドルに迫る
  • Prenetics所有のACT GenomicsがACTOncoのFDA認可を取得
  • アジレント、がん調査向け高性能NGSターゲットエンリッチメントワークフローの開発会社Avida Biomedの買収を発表
  • プレネティクスがACTゲノミクスを買収
  • ロシュ社、エンヘルトゥの適応となるHER2低発現転移性乳がん患者を特定する初のコンパニオン診断薬でFDAの承認を取得
  • CDC、がんムーンショット目標の推進に2億1,500万米ドルを授与

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
• FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
• FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 84. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 85. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 86. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 87. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 88. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 89. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 90. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 110. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 119. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 120. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 121. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 122. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 130. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 131. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 132. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 133. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 136. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 137. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 138. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 139. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 140. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 141. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 142. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 143. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 146. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 147. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 148. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 149. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 152. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 153. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 154. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 155. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 156. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 157. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 160. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 161. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 162. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 163. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 164. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 165. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 168. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 169. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 170. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 171. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 172. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 173. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 176. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 177. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 178. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 179. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 180. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 181. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 182. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 184. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 186. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 188. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 192. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 193. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 194. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 195. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 196. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 197. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 200. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 201. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 202. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 203. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 204. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 205. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 206. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 207. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 208. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 209. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 210. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 211. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 212. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 213. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 225. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 226. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 227. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 228. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 229. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 230. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 231. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 234. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 235. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 236. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 237. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 238. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 239. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 240. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 241. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 242. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 243. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 244. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 245. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 246. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 247. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 248. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 249. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 250. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 251. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 252. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 253. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 254. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 255. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 258. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 259. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 260. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 261. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 262. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 263. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 264. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 265. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 266. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 267. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 268. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 269. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 270. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 271. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 274. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 275. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 276. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 277. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 278. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 279. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 282. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 283. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 284. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 285. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 286. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 287. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 288. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 289. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 290. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 291. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 292. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 293. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 294. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 295. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 296. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 297. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 298. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 299. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 300. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 301. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 302. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 303. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 304. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 305. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 306. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 307. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 308. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 309. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 310. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 311. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 312. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 313. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 314. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 315. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 316. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 317. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 318. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 319. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 320. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 321. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 322. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 323. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 324. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 325. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 326. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 327. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 328. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 329. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 331. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 332. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 333. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
• TABLE 334. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
• TABLE 335. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 336. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE,

[199 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient's tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, refiecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Immunoassays
  • In-Situ Hybridization
  • Mass Spectrometry
  • Microarrays
  • Next-Generation Sequencing
  • Polymerase Chain Reaction

• Biomarker Type
  • Genomic Biomarker
  • Protein Biomarker

• Cancer Type
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Prostate Cancer

• Application
  • Biomarker Discovery
  • Clinical Application
  • Diagnostics
  • Personalized Medicine
  • Prognostics
  • Research
  • Screening
  • Treatment & Monitoring

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer/Tumor Profiling Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?

3. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?

4. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?

5. Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
    • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
    • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
    • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
  • 5.1.4. Challenges
    • 5.1.4.1. Low biomarker discovery-to-approval ratio
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
  • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
  • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
  • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
• 5.3. Market Trend Analysis
  • 5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
  • 5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
  • 5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Cancer/Tumor Profiling Market, by Technology

• 6.1. Introduction
• 6.2. Immunoassays
• 6.3. In-Situ Hybridization
• 6.4. Mass Spectrometry
• 6.5. Microarrays
• 6.6. Next-Generation Sequencing
• 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

• 7.1. Introduction
• 7.2. Genomic Biomarker
• 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Colorectal Cancer
• 8.4. Lung Cancer
• 8.5. Melanoma Cancer
• 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

• 9.1. Introduction
• 9.2. Biomarker Discovery
• 9.3. Clinical Application
• 9.4. Diagnostics
• 9.5. Personalized Medicine
• 9.6. Prognostics
• 9.7. Research
• 9.8. Screening
• 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
  • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
  • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
  • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
  • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
  • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
  • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
  • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
  • 13.3.9. Prenetics Acquires ACT Genomics
  • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
  • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio